Seguimiento farmacoterapéutico a pacientes oncológicos con medicamentos de alto costo supervisados del hospital de Alta Complejidad Virgen de la Puerta
No Thumbnail Available
Date
2024
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
Objetivo: Detectar, prevenir y resolver a través del seguimiento farmacoterapéutico los problemas relacionados con los medicamentos de alto costo supervisados utilizados en pacientes oncológicos del Hospital de Alta Complejidad “Virgen de la Puerta”, contribuyendo a la mejora en la calidad de vida de los pacientes. Material y Métodos: Estudio observacional, longitudinal, cuantitativo y prospectivo utilizando como fuente de información, los formatos de seguimiento farmacoterapéutico y las historias clínicas virtuales y físicas de pacientes oncológicos, que incluían un medicamento de alto costo supervisado (MACS). Resultados: De los 32 pacientes que cumplieron con los criterios de inclusión, durante 6 meses, el 51.90% presentaron interacciones moderadas, 26.64 % interacciones con alimentos y 5.54 % mostraron la duplicidad terapéutica. Los problemas relacionados a los medicamentos (PRM) determinaron, que el 55.56% corresponde a PRM 1, el PRM 4 con 33.33 %. El número de reacciones adversas al medicamento (RAMs) presentadas fueron siete, las cuales fueron evaluadas como moderadas. Conclusiones: Durante el seguimiento farmacoterapéutico realizado a pacientes oncológicos, con MACS, se han determinado nueve pacientes con PRM que representan el 28.13% de estos; cinco PRM1, por falta de stock de los medicamentos; PRM3 se detectó uno debido a que no hubo respuesta favorable por parte del paciente, PRM 4 se detectaron cuatro, donde la dosis tuvo que ser disminuida por falta de stock del producto en la presentación de menor concentración. No se determinó ningún PRM de Seguridad problema en el resultado del tratamiento del paciente. Se realizaron 10 intervenciones farmacéuticas, dos realizadas al personal de enfermería y una al médico tratante y siete intervenciones a familiares/pacientes, de forma virtual; se resolvieron seis PRMs, por las intervenciones farmacéuticas realizadas.
ABSTRACT Objective: Detect, prevent and resolve through pharmacotherapeutic monitoring the problems related to high-cost supervised medications used in oncological patients at the “Virgen de la Puerta” High Complexity Hospital, contributing to the improvement in the quality of life of patients. Material and Methods: Observational, longitudinal, quantitative and prospective study using as a source of information, the pharmacotherapeutic follow-up forms and the virtual and physical medical records of oncology patients, which included a supervised high-cost medication (MACS). Results: Of the 32 patients who met the inclusion criteria, during 6 months, 51.90% presented moderate interactions, 26.64% interactions with food and 5.54% showed therapeutic duplication. Problems related to medications (PRM) determined that 55.56% correspond to PRM 1, PRM 4 with 33.33%. The number of adverse drug reactions (PRMs) presented was seven, which were evaluated as moderate. Conclusions: During the pharmacotherapeutic follow-up carried out on oncological patients with MACS, nine patients with PRM have been determined, representing 28.13% of these; five PRM1, due to lack of stock of medicines; PRM3, one was detected because there was no favorable response from the patient, PRM 4, four were detected, where the dose had to be reduced due to lack of stock of the product in the lower concentration presentation. No Safety PRM problem was determined in the patient's treatment outcome. 10 pharmaceutical interventions were carried out, two carried out to the nursing staff and one to the treating physician, and seven interventions to family members/patients, virtually; Six DRPs were resolved due to the pharmaceutical interventions carried out.
ABSTRACT Objective: Detect, prevent and resolve through pharmacotherapeutic monitoring the problems related to high-cost supervised medications used in oncological patients at the “Virgen de la Puerta” High Complexity Hospital, contributing to the improvement in the quality of life of patients. Material and Methods: Observational, longitudinal, quantitative and prospective study using as a source of information, the pharmacotherapeutic follow-up forms and the virtual and physical medical records of oncology patients, which included a supervised high-cost medication (MACS). Results: Of the 32 patients who met the inclusion criteria, during 6 months, 51.90% presented moderate interactions, 26.64% interactions with food and 5.54% showed therapeutic duplication. Problems related to medications (PRM) determined that 55.56% correspond to PRM 1, PRM 4 with 33.33%. The number of adverse drug reactions (PRMs) presented was seven, which were evaluated as moderate. Conclusions: During the pharmacotherapeutic follow-up carried out on oncological patients with MACS, nine patients with PRM have been determined, representing 28.13% of these; five PRM1, due to lack of stock of medicines; PRM3, one was detected because there was no favorable response from the patient, PRM 4, four were detected, where the dose had to be reduced due to lack of stock of the product in the lower concentration presentation. No Safety PRM problem was determined in the patient's treatment outcome. 10 pharmaceutical interventions were carried out, two carried out to the nursing staff and one to the treating physician, and seven interventions to family members/patients, virtually; Six DRPs were resolved due to the pharmaceutical interventions carried out.
Description
Keywords
Seguimiento farmacoterapéutico. Problemas relacionados al medicamento. Intervención farmacéutica. Medicamentos biológicos. Pacientes oncológicos.